You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 21, 2026

Claims for Patent: 11,324,735

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,324,735

Title:	Method of treatment with tradipitant
Abstract:	This application relates to a method of treatment with tradipitant, and more particularly, to a method of treatment of pruritus with tradipitant.
Inventor(s):	Mihael H. Polymeropoulos, Louis William Licamele
Assignee:	Vanda Pharmaceuticals Inc
Application Number:	US16/944,596
Patent Claims:	1. A method of administering tradipitant to a patient afflicted with a disorder ameliorated by administration of tradipitant, which comprises: orally administering to the patient tradipitant twice daily in a solid immediate release form comprising tradipitant and one or more pharmaceutically acceptable excipients, at a dose of 100 to 200 mg/day of tradipitant. 2. The method of claim 1, wherein the solid immediate release form is a capsule or a tablet. 3. The method of claim 1, wherein the dose of tradipitant is 50 to 100 mg twice daily (bid). 4. The method of claim 3, wherein the dose of tradipitant is 50 mg twice daily (bid). 5. The method of claim 3, wherein the dose of tradipitant is 85 mg twice daily (bid). 6. The method of claim 3, wherein the dose of tradipitant is 100 mg twice daily (bid). 7. The method of claim 1, wherein the disorder ameliorated by administration of tradipitant is caused by an over-expression of substance P or over-stimulation of the neurokinin-1 (NK-1) receptor. 8. The method of claim 1, wherein the disorder is pain, a behavioral stressor, craving, nausea, vomiting, substance dependence, anxiety, pruritus, or atopic dermatitis. 9. A method of administering tradipitant to a patient afflicted with a disorder ameliorated by administration of tradipitant, which comprises: orally administering to the patient tradipitant once daily in a solid immediate release form comprising tradipitant and one or more pharmaceutically acceptable excipients, at a dose of 150 to 200 mg/day of tradipitant. 10. The method of claim 9, wherein the solid immediate release form is a capsule or a tablet. 11. The method of claim 9, wherein the disorder ameliorated by administration of tradipitant is caused by an over-expression of substance P or over-stimulation of the neurokinin-1 (NK-1) receptor. 12. The method of claim 9, wherein the disorder is pain, a behavioral stressor, craving, nausea, vomiting, substance dependence, anxiety, pruritus, or atopic dermatitis. 13. The method of claim 9, wherein the dose of tradipitant is 170 mg/day.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.